Rockwell Medical (RMTI +9.7%) is having a strong session.
Helping the cause may be the announcement that a Triferic study (PRIME) was selected as best abstract submitted to the 34th Annual Dialysis Conference.
In PRIME, Triferic (when regularly administered) lowered ESA usage "while maintaining iron balance and maximizing iron delivery."
RMTI hopes that between PRIME and the CRUISE trials, there is enough evidence to show that Triferic can "establish a new paradigm in iron therapy treatment for hemodialysis patients." (PR)
A bit of controversy surrounding this issue flared up last month thanks to a negative note out of Brean.